Alnylam
Generated by Meeveem AI
"Pioneering RNAi therapeutics that silence disease causing genes"
Cambridge, MA
•1000+ Employees
•Biotechnology
About Alnylam
Alnylam Pharmaceuticals pioneers RNA interference therapeutics, an innovative medicine class that silences genes causing disease. Since 2002, it has transformed Nobel Prize winning science into clinical reality, securing six medicine approvals for previously untreatable conditions. Its pipeline addresses rare genetic disorders and common diseases across therapeutic areas. The company operates at the intersection of genetic discovery and patient care. By preventing harmful proteins from being made, Alnylam medicines work at the molecular level. This approach opens treatment possibilities for conditions once beyond reach, bringing hope to patients worldwide.
Illustrative visual - may not reflect the actual offering.
Illustrative visual - may not reflect the actual offering.
2500
Team Members
2002
Founded
Public
Funding
Hybrid
Work Environment
Our Vision
A world where genetic diseases are no longer untreatable, where silencing a single harmful gene can restore health, and where patients once without options can live full lives amplified by transformative medicines.
Our Mission
Alnylam pioneers RNA interference therapeutics to silence the genes that cause disease, translating breakthrough science into transformational medicines for patients with rare and prevalent conditions worldwide.